Endocrinology · Obesity and Type 2 DiabetesTrial Updateclinicalmid-term

Study on Quercetin's Impact on Glucose Absorption in Obesity and Type 2 Diabetes

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/3/2026, 6:30:25 PM

Assessment confidence: 62% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

This clinical trial on quercetin's effects on glucose absorption could redefine treatment strategies for obesity and type 2 diabetes. Successful outcomes may lead to new dietary interventions, impacting existing treatment paradigms and portfolio strategies for pharma companies in this therapeutic area. Regulatory context from FDA (FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 Diabetes) supports the near-term read. Assessment grounded in 20 ranked evidence items (8 high-relevance).

Strategic Assessment

If successful, this could lead to the development of quercetin as a complementary treatment option, influencing portfolio strategies for companies focused on diabetes and obesity. The strongest clinical anchor is Investigating the Use of Quercetin on Glucose Absorption in Obesity, and Obesity With Type 2 Diabetes (ClinicalTrials.gov), entity match (national institute of diabetes and digestive and kidney diseases). In Endocrinology · Obesity and Type 2 Diabetes, 4 regulatory and 3 competitive items passed relevance filtering for National Institute of Diabetes and Digestive and Kidney Diseases.

Competitive Pressure

The most relevant competitive pressure comes from [Ad hoc announcement pursuant to Art. (Roche) — sponsor/company relevance (roche). Secondary pressure from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study. This study could provide insights into a potential new dietary intervention for managing glucose levels in obesity and diabetes, impacting current treatment paradigms.

Regulatory Outlook

Regulatory risk is concentrated around FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 Diabetes (FDA). Regulatory pathway relevance (approval). Relevant agencies in corpus: FDA, MHRA. Positive trial results could lead to new regulatory pathways for quercetin as a treatment option, influencing labeling and compliance requirements for dietary interventions in diabetes management.

Key Risks

Elevated medium regulatory exposure for National Institute of Diabetes and Digestive and Kidney Diseases could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If quercetin proves effective, it could open new revenue streams and enhance market share for companies developing treatments for obesity and diabetes, potentially altering competitive dynamics.
If successful, this could lead to the development of quercetin as a complementary treatment option, influencing portfolio strategies for companies focused on diabetes and obesity.

What Would Change This Assessment

This becomes more urgent if Monitor results from the oral glucose tolerance tests and overall trial outcomes for potential implications on treatment guidelines.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 Diabetes
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Clinical trials for medicines: modifying a clinical trial approval
MHRAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
FDA Approves Drug for Pediatric Stage 3 Type I Diabetes
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
FDA Clears First Over-the-Counter Continuous Glucose Monitor for Children
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Investigating the Use of Quercetin on Glucose Absorption in Obesity, and Obesity With Type 2 Diabetes
ClinicalTrials.govhigh relevance
Entity match (national institute of diabetes and digestive and kidney diseases)
FDA document
View source
Trial to Optimize Just-in-Time Adaptive Intervention for Binge Eating & Weight-related Behaviors
ClinicalTrials.govhigh relevance
Entity match (national institute of diabetes and digestive and kidney diseases)
FDA document
View source
Scalable Behavioral Program for Weight Loss Maintenance After GLP-1 and Anti-Obesity Medication Discontinuation
ClinicalTrials.govhigh relevance
Entity match (national institute of diabetes and digestive and kidney diseases)
FDA document
View source
Antecedent Metabolic Health and Metformin Aging Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Cardiometabolic Impact of Produce Prescription Program in Patients With Type 2 Diabetes and Food Insecurity
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Early Feasibility Evaluation of the UniBE Hybrid Closed-loop Insulin Delivery System in Type 1 Diabetes: UBLoop-Genesis
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

[Ad hoc announcement pursuant to Art.
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Phase I/II Trial of Lentiviral Gene Transfer for XSCID in Children Over Two Years
Humanexa Signalsmedium relevance
Moderate corpus alignment

Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Impact of oliceridine versus sufentanil on postoperative nausea and vomiting in patients undergoing thyroid surgery: a prospective, double-blind, randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Risk Factors, Cancer Types and Prognostic Significance of Second Primary Cancer After Early-, Intermediate- and Late-Onset Colorectal Cancer: A Retrospective Study in Chinese High-Volume Cancer Center
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
12‑weeks fisetin supplementation and interval resistance with aerobic training: changes in Maresin‑1 and inflammatory markers in men with obesity: a randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effect of pasteurized Akkermansia muciniphila MucT on insulin sensitivity, body composition, and GLP-1 production in subjects with metabolic syndrome: impact of low baseline gut Akkermansia levels.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13).
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

National Institute of Diabetes and Digestive and Kidney Diseases
obesity treatment market
type 2 diabetes treatment market

Commercial impact

medium

If quercetin proves effective, it could open new revenue streams and enhance market share for companies developing treatments for obesity and diabetes, potentially altering competitive dynamics.

Regulatory impact

medium

Positive trial results could lead to new regulatory pathways for quercetin as a treatment option, influencing labeling and compliance requirements for dietary interventions in diabetes management.

What to watch

Monitor results from the oral glucose tolerance tests and overall trial outcomes for potential implications on treatment guidelines.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.